RBC Capital Raises Price Target for Amgen (NASDAQ: AMGN) Amid Strong Outlook

• RBC Capital has increased its price target for Amgen, signaling strong analyst confidence in the biopharmaceutical company's future performance.
• Amgen demonstrated robust stock performance, outperforming both the S&P 500 and the broader medical sector over the past month.
• Analysts project positive financial growth for Amgen, with anticipated increases in both quarterly earnings per share (EPS) and revenue.

Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, develops innovative medicines for serious diseases, competing with other drugmakers for market share and patient access. RBC Capital has maintained its Outperform rating on the stock, demonstrating confidence in its future performance, and has raised its price target to $430.00 from $400.00. An Outperform rating signifies that RBC analysts anticipate the stock will perform better than the broader market.

This new price target represents a premium of $16.92 above the $413.08 share price at the time RBC released its update. It's important to note that a price target reflects an analyst’s estimate of where a stock could trade, not a guaranteed investment return. Amgen’s current market capitalization stands at approximately $222.90 billion, highlighting its significant presence in the pharmaceutical industry.

As highlighted by Zacks, Amgen closed at $413.08 on October 7, 2026, marking an increase of $10.48, or 2.60%, from the previous trading session. In contrast, the S&P 500 index experienced a slight decline of 0.22% on the same day. Over the preceding month, Amgen demonstrated robust stock performance, gaining 2.40%, significantly outperforming the S&P 500's 1.40% rise and contrasting with a 4.73% decline observed in the broader medical sector.

Looking ahead, analysts project Amgen’s earnings per share (EPS) to reach $5.69 for the upcoming quarter, representing a 0.89% increase from the prior year. Quarterly revenue is forecasted to hit $9.91 billion, an impressive 3.68% growth. Earnings per share is a key financial metric measuring a company's profit divided by its outstanding shares. Zacks further indicates a consensus full-year earnings estimate of $22.94 per share for the biopharmaceutical giant.